Immunology
CuraCell granted approval for trial of new therapy for metastatic cancers
August 13, 2025Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer
Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
August 3, 2025Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
July 29, 2025Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …
Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes
July 10, 2025Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …
Richard Philipson appointed as chief medical officer of Hansa Biopharma
July 9, 2025Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology
Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
June 30, 2025Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
FDA grants orphan drug designation to antibody-mediated rejection treatment
June 26, 2025Research and Development FDA, Immunology, Orphan Drug Designation, Sanofi, antibody-mediated rejection, clinical trials, immunology, inflammation, organ transplantation
Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to riliprubart for …
Meteor Biotech opens site at UCLA to support biotech research
June 11, 2025Biotech/start-up, Research and Development, Sales and Marketing Devices, Immunology, Meteor Biotech, Oncology, Pharmacy, University of California Los Angeles, cell sorting technology, clinical trials, research facility
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international office at the California NanoSystems …
Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research
June 10, 2025Conferencing, Events & Incentives, Interactive Conferences, Medical Communications, Research and Development, Sales and Marketing Guillain-Barré syndrome, Hansa Biopharma, Immunology, Neurology, investor event
Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 June 2025. The webcast aims …
Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome
May 15, 2025Research and Development Guillain-Barré Syndrome (GBS), Hansa Biopharma, Immunology, Peripheral Nerve Society (PNS) Annual Meeting, Rare Diseases
Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
May 15, 2025Medical Communications, Sales and Marketing Corporate, European Innovation Council (EIC), Immunology, Neogap Therapeutics, US pharma market, biotech, immunotherapy
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences …
Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
May 14, 2025Research and Development Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May …
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
Latest content
The evidence bar impacting UK medical cannabis access
Addressing the rheumatic disease diagnostic gap in primary care
